Oasmia Pharmaceutical AB (NASDAQ: OASM) was founded in 1988 and is headquartered in Uppsala, Sweden, with 57 full-time employees. It is a biopharmaceutical company focusing on innovative therapies for human and animal tumors.
Oasmia Pharmaceutical (OASM):
Oasmia Pharmaceutical Company mainly develops, produces, markets and sells human and veterinary oncology drugs in Sweden, focusing on manufacturing formulations based on cell inhibitors.
Oasmia Pharmaceutical’s approved products include Paclical / Apealea for the treatment of ovarian and metastatic breast cancer; and Doxophos for the treatment of various doxorubicin indications.
In addition, Oasmia Pharmaceutical also develops Docecal for breast cancer; OAS-19 and KB9520 for various cancers; Paccal Vet for breast and squamous cell carcinoma; and Doxophos Vet for lymphoma.
Oasmia Pharmaceutical (OASM) investment:
The company submitted the prospectus on 7/6/2015 and plans to land on Nasdaq on October 23, 2015. The issue price is US$4.1, the raised funds are US$23 million, and the stock code is OASM.